Dr. Anastassov also noted the company received two patent allowances for cannabinoids -based ophthalmic solutions, which are used to treat glaucoma and conjunctival inflammation. It also has filed a new patent for a chewing gum that has a “controlled release of cannabinoids and opioid agonists and … Read More
The post AXIM Biotechnologies Reports Fiscal 2017 Results, Says Making “Solid Progress” appeared first on Dagga Magazine.